After five years of unprecedented momentum, the ADC field now finds itself at an interesting inflection point. With more programs in development and greater industry prioritization than ever before, ...
Two years after AstraZeneca splashed out $1 billion upfront for rights to Daiichi Sankyo's TROP2-targeting antibody-drug conjugate DS-1062, the drug has generate promising results in advanced ...
6 analysts have issued ratings. Wall Street analysts rate ADCT as Very Bullish on average, for a Wall Street consensus of buy. View ADCT’s ratings here. ADC Therapeutics SA is currently listed on NYSE ...
This price reflects trading activity during the overnight session on the Blue Ocean ATS, available 8 PM to 4 AM ET, Sunday through Thursday, when regular markets are closed. Chart does not reflect ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results